Mercury Laboratories Ltd (BSE: 538964) is a Vadodara, Gujarat-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹91 Cr, it ranks #3,358 by market cap among the 6,137 Indian listed companies on FinBizNet, and #72 of 86 in Medicinal Chemicals and Botanical Products. At ₹731.05 (as of 25 Oct 2026), the share price is 21.3% below its 52-week high of ₹928.50 and 17.8% above its 52-week low of ₹620.55. The share price is down 18.8% over one year and down 12.4% over three months.
| Current Price | ₹731.05 |
|---|---|
| Market Cap | ₹91 Cr |
| BSE Code | 538964 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 18.5 |
| Return on Equity | 8.66% |
| Return on Assets | 4.90% |
| 52-Week Range | ₹620.55 – ₹928.50 |
| 1-Year Price Change | -18.8% |
| 3-Month Price Change | -12.4% |
| Beta (1Y) | 0.47 |
| Dividend Yield | 0.47% |
| Headquarters | Vadodara, Gujarat |
| Website | www.mercurylabs.com |
Mercury Laboratories Limited engages in manufacturing, selling, exporting, and dealing in various pharmaceutical drugs and medicines for mother and child healthcare in India and internationally. The company offers analgesic, anti-inflammatory, anti-pyretic, anthelmintic, antibiotic, anti-coagulant, anti-platelet, bleeding agent, anti-fungal, anti-hypertensive, anti-malarial, cardiovascular system, central nervous system, eye, gastro-intestinal system, hypoglycemic/anti-diabetic, multivitamin, protein supplement, respiratory system, anti-allergic, steroids, urinary system, uterine stimulant, and other drugs; and formulations, including tablets, oral liquids, injections, small volume parenterals, and eye/ear drops. It also provides pharmaceutical products for PCOS and uterine disorders, galactagogue, haemostat, iron and vitamins, pain management, preterm labor management, antiemetic, PPI; vitamin K1, zinc supplement, antiallergic, vitamin D3, digestive enzyme, promolact, antipyretic, and
1. Pharmaceuticals Products-This segment develops, manufactures, markets, distributes, and sells pharmaceuticals, medicinal drugs, and formulations for mother and child healthcare.
1. Pharmaceuticals Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Mercury Laboratories Ltd | ₹91 Cr | 18.5 | 8.66% | — | -18.8% |
Listed by market capitalisation. Ratios are shown for context only.
Mercury Laboratories Ltd is trading at ₹731.05, with a market capitalisation of ₹91 Cr.
Mercury Laboratories Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Mercury Laboratories Ltd has a P/E of 18.5 and a return on equity of 8.66%.
Mercury Laboratories Ltd is listed on the BSE under the scrip code 538964.
Mercury Laboratories Ltd's share price is down 18.8% over one year and down 12.4% over three months. Its 52-week range is ₹620.55 to ₹928.50.
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.